As you might expect, the competition to win a share of the expanding GLP-1 market is fierce right now, with giants Novo ...

Pfizer has secured a $10 billion acquisition of obesity drug developer Metsera, outbidding rival Novo Nordisk in a heated ...

As the race to develop oncology bispecifics heats up, Pfizer has offered a first look at its strategy to dethrone Keytruda and establish its ...

On Monday, 10 November 2025, the healthcare world was abuzz as two pharmaceutical giants, Pfizer and Novo Nordisk, fiercely ...

On November 4, 2025, just a day after Pfizer filed its suits against Novo Nordisk and Metsera, Novo Nordisk submitted an ...

By updating the genetic code inside mRNA vaccines every year, scientists can keep population-level immunity aligned with ...

The fate of the enhanced Affordable Care Act premium tax credits — initially bolstered during the pandemic — is still unclear ...

The first thing that comes to mind when we speak about the S&P 500 is the biggest tech companies, high valuations, and ...

Cogent Biosciences, Inc. stock soars after bezuclastinib's strong Phase 3 results in GIST. Click for my updated look at COGT ...

A streamlined workflow using Six Sigma's DMAIC methodology was developed to identify and mitigate visible particles in ...

Companies don’t generally cut prices out of generosity.

Novo Nordisk (NYSE:NVO) climbs about 2% on Monday afternoon after it says it will not raise its offer for Metsera ...